Trial reportThe Journal of urology2008
Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study.
Trial report in The Journal of urology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 117 citations in OpenAlex.
- Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2012Pooled it
- NCCN Task Force Report: Bone Health in Cancer Care.Journal of the National Comprehensive Cancer Network : JNCCN · 2009Guideline
- Trial
- Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2010Trial
- Denosumab in men receiving androgen-deprivation therapy for prostate cancer.The New England journal of medicine · 2009Trial
- Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2008Trial
- Molecular Docking and ADMET Analysis Strategy-based Stability Indicating RP-HPLC-PDA Method Development and Validation of Toremifene.Current computer-aided drug design · 2025Article
- Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer.Journal of bone and mineral metabolism · 2023Review
- A Systematic Study of the Impact of Estrogens and Selective Estrogen Receptor Modulators on Prostate Cancer Cell Proliferation.Scientific reports · 2020Article
- Decrease of bone mineral density in Japanese patients with non-metastatic prostate cancer treated with androgen deprivation therapy.Journal of bone and mineral metabolism · 2019Article
- Cancer Treatment and Bone Health.Calcified tissue international · 2018Review
- Estrogen and Androgen Blockade for Advanced Prostate Cancer in the Era of Precision Medicine.Cancers · 2018Review
- Evaluation and management of skeletal disease in cancer care.Critical reviews in oncology/hematology · 2017Review
- Antiresorptive therapy in the management of cancer treatment-induced bone loss.Current osteoporosis reports · 2015Review
- Article
- Atypical McMurry cross-coupling reactions leading to a new series of potent antiproliferative compounds bearing the key [ferrocenyl-ene-phenol] motif.Molecules (Basel, Switzerland) · 2014Article
- Estrogen receptors in prostate development and cancer.American journal of clinical and experimental urology · 2014Review
- Selective estrogen receptor modulators: tissue specificity and clinical utility.Clinical interventions in aging · 2014Review
- Optimal bone health management strategies in patients with prostate cancer.Indian journal of urology : IJU : journal of the Urological Society of India · 2013Article
- Bone-targeted agents: preventing skeletal complications in prostate cancer.The Urologic clinics of North America · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
purposeWe evaluated the effects of toremifene on bone mineral density, a surrogate for fracture risk, in men receiving androgen deprivation therapy for prostate cancer. MATERIALS AND
methodsIn an ongoing, multicenter, phase 3 fracture prevention study 1,392 men 50 years or older with prostate cancer receiving androgen deprivation therapy were randomized to 80 mg toremifene per day or placebo. Bone mineral density of the lumbar spine, total hip and femoral neck was assessed using dual energy x-ray absorptiometry. In this planned interim analysis of the first 197 subjects we compared bone mineral density changes from baseline to month 12 between the placebo and toremifene groups.
resultsCompared with the placebo group men in the toremifene group had significant increases in bone mineral density at each evaluated skeletal site. Lumbar spine bone mineral density decreased 0.7% in the placebo group and increased 1.6% in the toremifene group (between group comparison p <0.001). Total hip bone mineral density decreased 1.3% in the placebo group and increased 0.7% in the toremifene group (p = 0.001). Femoral neck bone mineral density decreased 1.3% in the placebo group and increased 0.2% in the toremifene group (p = 0.009). Between group differences in the change in bone mineral density from baseline to month 12 were 2.3%, 2.0% and 1.5% for the lumbar spine, total hip and femoral neck, respectively.
conclusionsToremifene significantly increased hip and spine bone mineral density in men receiving androgen deprivation therapy for prostate cancer. The effect of toremifene on the fracture risk is being assessed in the ongoing randomized, controlled trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.